Viridian Therapeutics, Inc. VRDN Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $212.38M+113% | $99.59M-3.1% | $102.83M-33.9% | $155.58M+268% | ||
| $662.27M+7.2% | $617.99M+65.0% | $374.54M+39.3% | $268.97M+73.9% | ||
| $894.23M+21.1% | $738.46M+51.8% | $486.48M+12.8% | $431.17M+115% | ||
| $1.23M-0.6% | $1.24M-26.1% | $1.67M+26.1% | $1.33M+254% | ||
| $899.42M+21.1% | $742.4M+51.4% | $490.42M+12.7% | $435.09M+114% | ||
| $8.68M+305% | $2.14M-4.3% | $2.24M-84.3% | $14.23M+511% | ||
| $367K+27.4% | $288K0.0% | $288K0.0% | $288K-0.3% | ||
| $70.7M+47.7% | $47.87M+79.7% | $26.64M-20.1% | $33.35M+145% | ||
| $34.24M— | $0-100% | $20.21M+335% | $4.65M— | ||
| $20.03M-71.7% | $70.76M+46.2% | $48.4M+20.9% | $40.03M+150% | ||
| 200M+24,591% | 810K+50.0% | 540K+30.4% | 414K+73.2% | ||
| -$1.34B-34.4% | -$995.86M-37.2% | -$725.91M-48.7% | -$488.17M-36.2% | ||
| $722.17M+7.5% | $671.64M+51.9% | $442.02M+11.9% | $395.06M+110% | ||
| $899.42M+21.1% | $742.4M+51.4% | $490.42M+12.7% | $435.09M+114% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Viridian Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 15.15 — current assets exceed current liabilities.
- Where does Viridian Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Viridian Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.